Immunome, Inc. (IMNM)
$17.58-8.20%Close
SELLCRISIS · day 14
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.7B
- Beta
- 2.13
- P/E (TTM)
- -6.92
- Short % float
- 21.15%
- Days to cover
- 9.9
- SI change
- +3.2%
- 1W
- -8.96%
- 1M
- -28.39%
- vs SPY 1W
- -8.82%
- vs SPY 1M
- -30.90%
Industry peers
FMP comparable companies · ranked by market cap
- SLSSELLSELLAS Life Sciences Group, Inc.$2.3BRECOVERYQ -8$12.41+4.02%
- CLDXSELLCelldex Therapeutics, Inc.$1.9BCRISISQ 5$28.25-4.01%
- IMCRSELLImmunocore Holdings plc$1.4BBEARQ 1$27.82-4.20%
- IMTXSELLImmatics N.V.$916MCRISISQ 5$6.83-5.27%
- CRVSSELLCorvus Pharmaceuticals, Inc.$791MCRISISQ 12$9.41-6.37%
- AVBPSELLArriVent BioPharma, Inc.$749MCRISISQ -6$16.09-2.25%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on IMNM?
- LOPJLB’s latest quantitative signal on Immunome, Inc. (IMNM) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is IMNM in?
- Immunome, Inc. (IMNM) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Immunome, Inc. (IMNM) do?
- Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosi…